Spesana Announces Agreement with Protean BioDiagnostics to Advance Precision Medicine at the Point of Care
MEMPHIS, Tenn. (PRWEB) May 09, 2023 -- Spesana, a company dedicated to improving patient care with an innovative, point of care precision medicine platform, has announced an agreement with Protean BioDiagnostics. This new agreement will amplify Protean’s mission to rapidly deploy innovative and clinically impactful tests. Clinicians are challenged by managing the growing complexity of laboratory testing services, especially in the areas of cancer diagnostics and delivery of precision health.
Protean simplifies the selection and management of patient testing for clinicians with its innovative MAPS™ system. This proprietary system optimizes patient care by efficiently providing and integrating test results, in accordance with continually updated official guidelines, effectively delivering comprehensive decision support, and offering telemedicine-based consultation support.
“Physicians asked for ways to optimize testing on minimal tissue or blood samples. We're excited to partner with Protean BioDiagnostics who can provide enhanced lab services to enable precision medicine for these clinicians,” said Carla Balch CEO of Spesana.
As a part of Spesana’s Precision Medicine Platform, Protean will be supported by efficient ordering, tracking, and reporting workflows in addition to education and communication capabilities. The result is increased access to Protean’s growing list of laboratory diagnostics by clinicians seeking advanced treatment options for their patients.
“We are excited to be working with Spesana to make Protean’s innovative MAPS™ system readily available to more clinicians and patients, and to be on the cutting edge of the precision medicine revolution that will positively transform patient care,” said Dr Magliocco Protean’s Founder and CEO.
About Spesana
Spesana has developed a healthcare platform for all therapeutic areas in all settings of care to increase the velocity of patients moving to the right specialists with a unified medical record. Important to the mission is the focus on precision medicine, notably molecular diagnostics, and clinical collaborations to allow physicians, patients, and insurance teams to come together around the best available therapies and new clinical trials for patients. The company was founded by oncology information technology trailblazer Carla Balch and an experienced team known for building the first certified electronic medical record platform in oncology. Spesana creates real-time collaborations, decision support based on real-world data and molecular diagnostics results.
LinkedIn: spesanaco | http://www.spesana.com
About Protean BioDiagnostics
Protean BioDiagnostics Inc. is bringing precision care diagnostics to all patients, everywhere, through its innovative Protean MAPS™ System with integrated Virtual Tumor Boards. In addition, Protean assists world-class pharmaceutical and biotech companies in developing clinical assays and companion diagnostics from its CLIA-certified, CAP-accredited laboratory in Orlando, FL. To learn more visit http://www.proteanbiodx.com
Dr Magliocco brings more than 30 years’ experience as a recognized global leader in the development of innovative cancer diagnostics to Protean.
Allen Rasoul, SPESANA, http://www.spesana.com, 1 9012546510, [email protected]
Share this article